In an era marked by accelerated technological advances and profound industrial transformations, allocate a fraction of the portfolio, as a 10-15%to emerging companies with high disruptive potential can constitute a bold and transformative strategy for any investor. These companies, still little recognized, are creating what could be the large companies of tomorrow. Although this type of investment carries high risk, the possible long-term rewards are immense, comparable to having bet early on on titans like Apple or Amazon.
The key is to identify companies that not only align with global megatrends, but also have the capacity to revolutionize entire industries or generate completely new markets. Disruptive companies often face a lot of uncertainty and challenges, but those who have confidence in their potential from the start can enjoy exponential returns.
In this article we will analyze five startups which, although still little known, could redefine fundamental sectors in the decades to come, creating exceptional opportunities for long-term investors.
Several of these companies are already forming is part of the portfolio I’m building for my 19 year old twinss, particularly in the part intended for disruptive investments with a very long-term perspective. As I often say, for better or worse, my children will remember these decisions 25 years from now.
Nanodimension (NNDM)
Specializing in 3D printing technology, Nano Dimension is revolutionizing advanced electronic manufacturing. Focusing on printing printed circuit boards (PCBs) and electronic components, the company seeks to transform the production of electronic prototypes and devices, dramatically reducing development times and making it easier to create designs complex that would be unachievable with traditional methods. This positions them as a key player in the electronics industry, particularly in sectors where speed and flexibility are essential.
From a technical point of view, the most striking thing is to see how the shares of Nano Dimension, listed on the stock market in 2016, 70-80 dollarshave been laying the foundations for a floor at $2-2.05 for several years. Given this support, I would not be surprised if we could see another significant upward move, which could be similar to what we saw during the 2020 lows that led to US stock. 0.50 to 18 years dollars. If this is the case, it would mean that in the coming years the price could increase in search of $50. Currently, the company trades around $2.35 and with stop at 2 dollars This could be a call option with a very powerful risk-reward equation. I’m talking to you about going there with a stop at 2 dollars, but I don’t think it would be a bad thing for them to buy without having to use this stop since this strategy involves looking for investments in disruptive companies. Therefore, I do not exclude that he could threaten to lose the 2 dollars, go for 1.50 and then wake up for 50 dollars. Use a stop At $2, this drop would have protected your investment, but we would not have followed the plan and roadmap to continue seeking increases in the years to come.
We will find indications that Nano Dimension may have bottomed at $2 if it overcomes the resistances at $3 and $3.65.
Oklo (OKLO)
Oklo is an emerging company in the nuclear energy sector, focused on the development of advanced and small-scale reactors. Unlike conventional reactors, Oklo reactors are designed to be inherently safe and durable, capable of operating for decades without the need for refueling. Their technology not only has the potential to significantly reduce the cost and environmental impact of nuclear power, but can also make it accessible to smaller regions, providing a stable source of clean energy.
Technically, everything indicates that this company is on the way to returning to the highs of the year. $18.80of which I do not exclude the possibility that this company’s technology will ultimately be the one that succeeds in meeting the energy demand required by AI.
LightPath Technologies (LPTH)
LightPath Technologies specializes in the development of advanced optical components, including lenses and infrared solutions for industrial, medical and defense applications. Their expertise in the design and manufacturing of optical products helps advance critical technologies, such as sensors and communications systems. With growing demand for technologies such as computer vision, augmented reality and sensing systems, LightPath is well-positioned to play a central role in the development of next-generation devices.
From a technical point of view, we are talking about another company that at the time experienced an explosion to the heights reached in 2000 around 500 dollarsafter which it underwent a downward trend that only found a floor at the 2008 lows around $0.30. Since then, it has been moving sideways in an upward manner and now it is interesting since it is the bottom of the channel which limits this increase. Until the stock rises again from there, you can buy in the hope that this company’s technology will win the game in its field.
Xbiotech (XBIT)
XBiotech is developing a new generation of natural antibody-based treatments, primarily focused on inflammatory diseases and cancer. Unlike commonly used artificial antibodies, XBiotech’s antibodies mimic the natural processes of the immune system, which could improve effectiveness and reduce side effects. Their approach could represent a significant change in the treatment of serious illnesses, improving patients’ quality of life and optimizing therapeutic response.
Technically, the company’s shares are at 260% of the levels where it IPOed in 2015. 25 dollarswhich was the resistance that stopped the increases in 2020. Everything indicates that Xbiotech aims to reach these 2020 and 2015 highs again.
Myneralys Therapeutics (MLYS)
Myneralys Therapeutics is an innovative biotechnology company dedicated to developing treatments for autoimmune and metabolic diseases. By focusing on therapies targeting the underlying mechanisms of these diseases, the company seeks to provide more effective and less invasive solutions. Its scientific platform aims to develop personalized treatments that could change the paradigm for the management of complex and chronic diseases, giving hope to patients who until now had limited options.
Technically, the most notable is how the price is about to break the ceiling of the consolidation process that has limited digestion in recent months, which appears in the 14 dollarssomething that would open the door to a return, at least, to the area where it was made public in the 18 dollars.
